All In Biotech

Drug Trial Radar · NCT07524413

Dynamic Plasma EBV DNA-Guided Risk-Adapted Treatment With Becotatug Vedotin (MRG003) Plus PD-1 Blockade in Locoregionally Advanced Nasopharyngeal Carcinoma

A Multicenter, Prospective Study of Risk-Adapted Treatment With Becotatug Vedotin (MRG003) Plus PD-1 Blockade Guided by Dynamic Plasma Cell-Free EBV DNA in Patients With Locoregionally Advanced Nasopharyngeal Carcinoma

Last checked: Nov 19, 2026Latest source record: Oct 27, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

298

Planned (sponsor's estimate)

Start

Dec 2026

Primary completion

Dec 2031

Study completion Dec 2033

Sponsor

Lead sponsor
Sun Yat-sen UniversityAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Apr 13, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the efficacy and safety of a risk-adapted treatment strategy incorporating induction therapy with becotatug vedotin (MRG003) plus pucotenlimab, followed by treatment allocation based on post-induction plasma cell-free Epstein-Barr virus DNA (cfEBV DNA) status and radiographic response in patients with locoregionally advanced nasopharyngeal carcinoma. All participants will receive three cycles of induction therapy with becotatug vedotin (MRG003) plus the PD-1 inhibitor pucotenlimab. After induction therapy, participants with cfEBV DNA clearance and a complete or partial response will be classified as low risk and receive intensity-modulated radiotherapy alone, followed by adjuvant pucotenlimab. Participants without cfEBV DNA clearance or with stable or progressive disease will be classified as high risk and receive intensity-modulated radiotherapy with concurrent cisplatin, followed by adjuvant pucotenlimab and capecitabine. The primary objectives are to evaluate the post-induction therapy complete response rate in the overall study population and event-free survival in the high-risk group.

Conditions

  • Nasopharyngeal Cancinoma (NPC)
  • Nasopharyngeal Cancer

Interventions

  • Becotatug VedotinDrug

    Induction Therapy: Becotatug Vedotin (MRG003) 2.0 mg/kg, intravenous infusion, Day 1 (3 cycles, Q3W)

  • PucotenlimabDrug

    Induction Therapy: Pucotenlimab 200 mg, intravenous infusion, Day 1 (3 cycles, Q3W); Adjuvant Therapy: Pucotenlimab 200 mg, intravenous infusion, Day 1 (5 cycles, Q3W)

  • Intensity-Modulated RadiotherapyRadiation

    70 Gy in 33 fractions, once daily, 5 days per week

  • CisplatinDrug

    Concurrent Chemoradiotherapy: Cisplatin 100 mg/m², intravenous infusion, Day 1 (2 cycles, Q3W)

  • CapecitabineDrug

    Adjuvant Therapy: Capecitabine 650 mg/m², orally twice daily, Days 1-21 (17 cycles, Q3W)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Post-induction Therapy Complete Response Rate (post-IT CRR)Time frame: Within 9 to 21 days after the last dose of induction therapy
  2. Event-Free Survival (EFS) in the High-Risk GroupTime frame: 3 years & 5 years

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.